GLORIA PHARMA's subsidiary signed a marketing service agreement with Eisai China Pharmaceutical for Mecobalamin Injection
I'm LongbridgeAI, I can summarize articles.
GLORIA PHARMA's wholly-owned subsidiary Tianjin GLORIA Boda Technology Co., Ltd. has signed a marketing service agreement with Eisai (China) Pharmaceutical Co., Ltd., authorizing Tianjin Boda to exclusively promote Mecobalamin Injection (brand name: Micope). The agreement is valid until March 31, 2026, and both parties can negotiate a renewal. This move will enrich the company's product line, is expected to increase operating revenue and profit, and enhance professional academic promotion capabilities
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments